AIMT News and Press, Aimmune Therapeutics Inc. From 09/16/19

Medmen Enterprises Inc (OTCMKTS:MMNFF) just announced that the waiting period under the Hart-   Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to its proposed   acquisition of PharmaCann, LLC. According to the release, the expiration of...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use ...

The FDA's Allergenic Products Advisory Committee voted 7 - 2 backing the efficacy of Aimmune Therapeutics' (NASDAQ: AIMT ) Palforzia (AR101) to reduce the incidence and severity of allergic reactions to peanut in young people aged 4 - 17 who have a confirmed diagnosis of peanut allergy. Mo...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Allergenic Products Advisory Commit...

Aimmune Therapeutics (NASDAQ: AIMT) has for a long time been desensitizing people with severe peanut allergies to their nemesis with AR101. In a nutshell, U.S. regulators recently gave the candidate, to be named Palforzia, a big push toward marketing approval and blockbuster sales. This doe...

Shares of Aimmune Therapeutics (NASDAQ: AIMT) , a clinical-stage biotech focused on severe allergic reaction prevention, are jumping after an indirect push forward from the FDA. The regulator released a briefing document ahead of this Friday's advisory committee meeting to discuss the compa...

Yuma Energy (NYSEMKT: YUMA ) +69%   announces third party purchase of senior secured bank debt. More news on: Yuma Energy, Inc., T2 Biosystems, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...

The FDA's Allergenic Products Advisory Committee will meet on Friday, September 13, to review and discuss Aimmune Therapeutics' (NASDAQ: AIMT ) marketing application for AR101, branded as Palforzia, to reduce the incidence and severity of allergic reactions to peanut in young people aged 4 -...

The biopharmaceutical industry's summer doldrums will unofficially come to a close this week thanks to steady gusts of wind from the Food and Drug Administration, plus a slate of presentations in front of scientists and investors. Some events are more important than others. If you only hav...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...